Ovid 10-Q: $20.8M Q3 Loss, $161.4M Cash, Cowen ATM Replaced by $75M Cantor Facility
OVID has more than doubled off its 52-week low of $1.18 on elevated volume (3.3× avg).
Summary
Ovid's Q3 10-Q shows a $20.8 million quarterly loss against $161.4 million of cash and securities. It also discloses that the Cowen ATM was terminated on November 9, 2026 in favor of a new $75.0 million Cantor facility.
Key Events · Earnings and Guidance · OVID
-
Q3 Loss Widens on Clinical Spend
Net loss was $20.8 million, or $0.10 per share, versus $12.2 million ($0.17 per share) a year earlier. R&D rose to $15.7 million from $5.9 million on OV329 and OV4071 study activity.
-
Cash Position Nearly Doubles
Cash, cash equivalents and marketable securities totaled $161.4 million at September 30, 2026, up from $90.4 million at December 31, 2025. The increase reflects $56.2 million from the March 2026 private placement, $50.5 million net from Series A warrant exercises and $10.5 million net from Cowen ATM sales.
-
ATM Provider Swapped
The Cowen sales agreement was mutually terminated effective November 9, 2026, and a new $75.0 million Controlled Equity Offering sales agreement with Cantor Fitzgerald was signed the same day. That keeps an at-the-market dilution overhang in place.
-
Series B Warrants Still Outstanding
28,861,000 Series B Warrants at a $1.40 strike remain exercisable through October 6, 2030. If exercised in full, they could bring in up to $40.0 million of additional gross proceeds.
Analysis · OVID · Life Sciences
The balance sheet is the story here: $161.4 million in cash and securities at September 30 versus $90.4 million at year-end, funded by the March private placement, Series A warrant exercises and ATM sales. That said, the quarterly loss widened to $20.8 million from $12.2 million as OV329 and OV4071 trial spending ramped. Management's disclosure supports funding operations at least 12 months out, and the 8-K filed today extends that runway into 2029. The filing also confirms the financing machinery was swapped on November 9 — Cowen's sales agreement terminated and a new $75.0 million Cantor at-the-market facility put in place, which keeps a dilution overhang in front of holders. Separately, former CFO Jeffrey Rona's July 6, 2026 separation carries $526,000 of severance plus a $105,200 pro rata bonus and a consulting deal running to the end of 2027.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OVID was trading at $2.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $556.6M. The 52-week trading range was $1.18 to $3.11. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.